Login to Your Account



As First Step In Biogeneric Debate, Omnitrope Cleared

By Aaron Lorenzo


Thursday, June 1, 2006
The FDA approved the biosimilar product Omnitrope (somatropin [rDNA origin]), a follow-on version of a growth hormone drug, in a landmark decision that reverberated among both supporters and opponents. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription